Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Intellia Therapeutics, Inc. currently manages a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio shows 1 pending office action, indicating a point of active engagement with the patent office. This specific volume of activity suggests a focused approach to intellectual property management at this time.
The prosecution history is concentrated under 1 distinct examiner and within 1 distinct art unit. This level of concentration suggests a specific technical focus or a stage in portfolio development where the workload is handled by the individuals identified in the data. Practitioners can expect a consistent examination experience because 1 distinct examiner and 1 distinct art unit handle the filings.
JOHNSON, CHRISTOPHER LINDSAY is identified as the busiest examiner for this portfolio. This examiner is responsible for 1 busiest examiner pending action. Because this number matches the total of 1 pending office action for the company, the identified examiner is currently managing all active matters for Intellia Therapeutics, Inc. This alignment ensures that the prosecution strategy remains centralized under the review of JOHNSON, CHRISTOPHER LINDSAY.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHNSON, CHRISTOPHER LINDSAY | 1 | 46.9% | +81.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18287229 | LIPID NANOPARTICLES COMPOSITIONS | JOHNSON, CHRISTOPHER LINDSAY | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18287229 | LIPID NANOPARTICLES COMPOSITIONS | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §102§103DP | Non-Final OA | — | Pending | Oct 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial